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 Due to the increasing prevalence of multi-drug resistant (MDR) bacteria, it is now 
important to begin the search for novel means of defending against such resistant infections. 
Enterobacteriaceae is a clinically relevant family of bacteria that has shown extensive resistance 
to many antibiotics, especially after biofilm formation. Inhibitory poly-microbial interactions 
within this family have been observed. It is known that Citrobacter freundii (CF) growth is 
significantly inhibited by Klebsiella pneumoniae (KP) through a secreted protein. In this study, 
the potential KP bacteriocin was screened for its inhibitory effects on CF at various phases of 
biofilm development. The suspected KP bacteriocin was also tested for its ability to decrease the 
dosage of antibiotics necessary to inhibit CF growth. Using spectrophotometric analysis, it was 
shown that the combined treatment of streptomycin and the KP protein allowed a decrease in the 
minimum inhibitory concentration of streptomycin needed from 50 μM to 32 μM. The combined 
treatment also yielded increased inhibition at the initial attachment phase of CF infection, as well 
as after biofilm development. The study uses the secreted KP protein to show the use of poly-
microbial interactions within clinical applications. Future projects concerning this KP molecule 
can pursue the use of a C. elegans model to determine its efficacy in vitro.  
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 Throughout the history of human civilization, thousands of different infectious diseases 
have caused widespread morbidity and mortality. Such diseases are caused by what we call 
pathogens, a term used to describe the millions of infectious organisms that can cause human 
disease. Pathogens are primarily bacteria and viruses, but also include parasites and fungi (1). 
These microorganisms are almost always unseen by the naked eye, but are universally found in 
our environment. Bacteria belong to the domain eubacteria, alongside archaea and eukaryotes, 
which comprise all other organisms. There are over 30,000 formally named species of bacteria, 
and this number continues to grow at a rapid rate (2). Due to their particular importance in 
medicine, such bacteria are being taxonomically classified which new emerging biotechnologies 
using genome phylogenies (3). The vast majority of bacteria are nonpathogenic towards humans, 
meaning they cause no detectable disease upon exposure. The relatively few bacterial species 
that are known to cause human disease also present a wide range of differences among the 
species, such as their reservoir(s), pathogenicity, and overall virulence. Disease may result from 
acute exposure to the bacterial species, or even from an imbalance of an individual’s pre-existing 
microbiome, such as seen in the human digestive tract (4). The vast extent of morbidity and 
mortality caused by communicable bacterial diseases necessitates continued research in the field 
of pathogenic bacteriology and the search for effective treatments against such diseases.  
Antibiotic resistance: 
 Antibacterial drugs, commonly known as antibiotics, are naturally or synthetically 
synthesized compounds that are selectively toxic towards bacterial cells, meaning they harm 
bacterial cells while having no effect on our human cells and tissues. German immunologist Paul 
Ehrlich described antibiotic compounds as “magic bullets”, that are highly bactericidal yet 
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maintain host cell integrity (5). Antibiotic resistance refers to the ability of certain bacterial 
species to withstand the effects of certain antibiotic drug therapies. Different bacteria have 
exhibited resistance since the creation of some of the first antibacterial therapies during Erhlich’s 
time. Penicillin, one of the most well-known antibiotics, was developed by Alexander Fleming in 
the 1940s. Despite the Nobel Prize winning drug being incredibly effective at killing a majority 
of bacterial species, Fleming soon observed strains that were no longer harmed by penicillin as 
early as 1945 (6). As the demand for such antibiotics drugs rose, the appearance of resistant 
strains began to increase. The mechanisms of how antibiotic resistance spreads is an area of 
ongoing research, but many strains are thought to have acquired resistance to a particular 
antibiotic drug through horizontal gene transfer. One common example is through conjugation or 
environmental uptake of a cellular plasmid which contains a gene that confers resistance to a 
given antibiotic (7). 
 In 2018 the Center for Disease Control and Prevention (CDC) reports that more than 2 
million US residents will acquire a drug-resistant infection, and more than 23,000 may die from 
such infections (8). There are several factors contributing to the spread of antibiotic resistance, 
including the overuse of antibiotic drugs from healthcare professionals, patient non-compliance 
to the drug protocol, and the lack of monetary incentives for established pharmaceutical 
companies to dedicate research and development funding to discovering new antibiotic 
compounds. Due to the ever-increasing presence of resistant bacterial pathogens, other 
modalities of searching for bacteriostatic and bactericidal compounds needs to be considered. 
One such model, as presented in this research, is from an inhibitory molecule seen from the 




 Enterobacteriaceae is a taxonomic family classification of bacteria. Within the 
Enterobacteriaceae family, there are approximately 200 species. These species share many 
common characteristics, such as their Gram-negative cell wall and their rod-shaped morphology, 
known as bacilli (9). Bacteria of the Enterobacteriaceae family are commensal symbionts, 
meaning they exist in our environment (or even on/within our body) and cause no detectable 
disease in humans. However, there are a particular handful of Enterobacteriaceae species that are 
widely recognized for their devastating contagious diseases they have caused throughout history. 
Such notable species include those of Escherichia, Salmonella, Shigella, Citrobacter, Klebsiella, 
and Yersinia (10). The degree of morbidity and mortality caused by the virulence of each of the 
Enterobacteriaceae species differs drastically. For instance, certain Escherichia and Salmonella 
species are known to cause thousands of cases of acute food poisoning each year, while Yersinia 
pestis, the causative agent of the plague, is noted to have a case fatality of 50% or more if left 
untreated (11).  
 In modern medicine, the Enterobacteriaceae family is of particular importance for its 
causation of several nosocomial infections. Nosocomial infections, also referred to as hospital-
acquired infections, are those which originate from healthcare facilities, such as intensive care 
units within hospitals or other outpatient care facilities. The economic burdens of nosocomial 
infections are astronomical and continue to rise quickly. It has been cited that within the United 
States alone, nosocomial infectious collectively cost hospitals nationwide upwards of 50 billion 
dollars annually (12). Such nosocomial infections are often highly resistant to several common 
antibiotic drug therapies, further increasing their clinical and financial burden.  
 One notable genus within the Enterobacteriaceae family is Citrobacter. There are now 
more than 15 different species identified within the Citrobacter genus, many of which are found 
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throughout the environment in the soil and wastewater, and even within the human gut (13). 
Although the majority of the species are noninfectious to humans, species such as C. koseri (CK) 
and C. freundii (CF) are opportunistic infections, causing meaningful disease states in 
immunocompromised individuals. Among neonates, such infections can result in sepsis or 
meningitis. Among the elderly, immunocompromised, or immunosuppressed, Citrobacter 
infections can be present within the urinary tract, respiratory tract, wounds, bone, peritoneum, 
endocardium, meninges, and bloodstream (14). The most common among these infections are 
urinary tract infections (UTIs). There is no current vaccine therapy for infectious Citrobacter 
species. The majority of Citrobacter infections exist within a bacterial biofilm, where aggregates 
of bacteria exist within a complex carbohydrate structure that lends a greater defense against 
human immune cells, and better adherence to tissues. Similar to many other bacteria within the 
Enterobacteriaceae family, Citrobacter infections are often noted for their resistance to common 
antibiotic therapies. C. freundii often exhibits a higher degree of drug-resistance in comparison to 
C. koseri (15). A majority of C. freundii strains are resistant to antibiotic drugs such as ampicillin, 
carbenicillin, and cephalothin. In recent years, C. freundii has acquired resistance to newly 
developed drug treatments such as piperacillin, third-generation cephalosporins, and monobactams 
(16). β-lactamase production is also common among Citrobacter pathogens, further limiting the 
availability of drug choice for patients. It has even been observed that C. freundii encodes site-
specific recombinases that utilize specific integrases to incorporate genes into their own 
chromosome that allow resistance to various drugs (17). Although many Citrobacter species 
contain gene sequences in the parental chromosome that confer resistance to certain antibiotics, 
such as the stated β-lactamase production, Citrobacter drug-resistance has spread and become 
common via the mechanism of horizontal gene transfer between bacteria (18). Horizontal gene 
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transfer involves the exchange of DNA between two, or more, bacteria within the same generation 
through conjugation, transformation, or transduction. C. freundii maintains a relatively high copy 
number of plasmids that lend further resistance to other drug therapies, making certain strains 
multi-drug resistant (MDR) or extensively-drug resistant (XDR) (19). Upon infection with a MDR 
Citrobacter species, such self-transmissible plasmids can be transferred throughout the 
interspecies population of infection via conjugation from donor to recipient cells, or through 
environmental uptake of the plasmid via transformation. The nosocomial pathogen’s combination 
of a lack of effective drug treatments and preventative vaccines, alongside its high capacity for 
virulence among susceptible populations, demands ongoing and urgent investigation into the 
mechanisms of its drug resistance and development of new effective therapies to combat such 
infections.  
 Within the Enterobacteriaceae family is Klebsiella, which contains particular species that 
are of clinical significance, such as Klebsiella pneumoniae. Klebsiella species are found 
throughout nature, as well as part of the normal human flora of the nose, mouth, and intestines 
(20). Despite being a part of the normal human flora, K. pneumoniae also functions as an 
opportunistic pathogen, causing disease among very young, very old, or populations with pre-
existing conditions. Many of these cases result from a hospital-acquired infection, as with other 
Enterobacteriaceae bacteria (21). A notable characteristic of K. pneumoniae is its ability to 
produce a heavy extracellular polysaccharide, which also lends to its smooth, shiny appearance 
upon culturing. The presence of its capsule plays a key role in its virulence, allowing it to adhere 
to many tissues and avoid phagocytosis by human immune cells such as neutrophils and 
macrophages (22). The sticky carbohydrate capsule lends K. pneumoniae the ability to adhere to 
many abiotic surfaces as well, seen clinically in the infection of medically-implanted devices. As 
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with many of Enterobacteriaceae species, Klebsiella infections are often present as a biofilm, 
where the capsule helps the bacterial population aggregate together to better evade immune cells 
and shield antibiotic targets (21). This tendency towards biofilm formation is an important 
virulence property exhibited in Enterobacteriaceae as well within multiple other pathogenic 
bacteria. Other clinical manifestations of K. pneumoniae infections may result in UTIs, 
pneumonia, diarrhea, meningitis, or sepsis (23). Currently, there is no vaccine for Klebsiella 
infections. Similar to Citrobacter, many Klebsiella species exhibit various degrees of resistance to 
common antibiotic drug therapies. Nosocomial K. pneumoniae infections are often cited as drug-
resistant by mechanism of their drug-efflux pumps (24). Therefore, Klebsiella is another example 
of a genus within the Enterobacteriaceae family that indicates the need for better treatment against 
nosocomial Enterobacter infections.  
Bacterial Biofilms: 
 Bacterial infections often exist within a “biofilm”. A bacterial biofilm is a given 
population of bacteria, comprised of either the same or different species, growing on a living or 
inert surface or tissue (25). Planktonic bacteria are individual cells that are free-floating and 
unattached to any surface or other cells. This bacterial biofilm is the result of an aggregation of 
hundreds or thousands of planktonic bacteria coming together. The presence of the biofilm 
population, in comparison to individual planktonic cells, can greatly change many of the 
characteristics of the population, including its adherence to various surfaces and tissues, ability 
to evade host immune defenses, and heightened resistance to antibiotics. Recent analyses reveal 
that upwards of 80% of bacterial infections are the result of biofilm formation (26).  
 Biofilms formed from aggregated planktonic bacteria are highly complex and organized, 
leading to many emerging properties that benefit the entire population. It has been shown that 
when enough planktonic cells aggregate onto the same surface, gene expression changes among 
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certain bacteria within the population that leads to the production of sticky extracellular 
polysaccharides and other adhesive proteins (28). Such adhesive compounds result in a highly 
viscous and adherent biofilm. Biofilms have the ability to enter into a dormant state, where they 
are not able to be cultured yet remain viable, and will reactivate the population’s metabolism 
upon the detection of a more favorable environment. Biofilms have been observed to exhibit 
motility, as they detach collectively or in clumps in order to further spread infection to other 
tissue or seek more favorable environments after a period of dormancy (29). Due to the highly 
viscous matrix surrounding established biofilms, host immune cells, particularly neutrophils and 
macrophages, are far less efficient at digesting the bacterial cells via phagocytosis. For instance, 
human macrophages preferentially digest planktonic E. coli cells with far greater efficiency than 
compared to E. coli cells that have aggregated into a biofilm (30). Likewise, the ability to tightly 
adhere to human tissues further compounds the ability to establish persistent, or chronic, 
infections. One notable example is the persistent Pseudomonas infection present in patients with 
Cystic Fibrosis. P. aeruginosa biofilms produce an alginate matrix, combined with other proteins 
and DNA, that is highly viscous and attached to the host’s lungs (31). The strong adherence to 
the tissues in the lungs, along with the host’s suppressed ability to combat the bacterial infection, 
facilitates a highly chronic infection that requires extensive therapies. Other common bacterial 
infections that are due to biofilm formation are infections present within dental caries, urinary 
tract infections, kidney stones, and endocarditis (32).  
 The greatest emergent property of bacterial biofilms, in terms of clinical significance, is 
their augmented resistance to existing antibiotic therapies. Even bacterial strains that have high 
susceptibility to certain antibiotics will become less susceptible when grown within a biofilm 
state (33). The bacterial population within a particular biofilm will be heterogeneous in terms of 
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their growth state, with cells ranging from exponential growth to cells within a stationary phase. 
Therefore, many antibiotic drugs that are growth-dependent will not be effective on the 
population within a stationary phase (34). Reports indicate significantly increased rates of such 
horizontal gene transfer within the biofilm, leading to the spread of plasmid or chromosomal 
DNA that will lend resistance to antibiotics (35). There are also several other notable methods 
through which antibiotic resistance is exhibited and spread throughout a biofilm that are beyond 
the scope of this paper. The ongoing clinical manifestations of resistant biofilms has led to 
ongoing research looking into novel therapies against such infections.  
 Klebsiella and Citrobacter exhibit high degrees of biofilm formation that plays a key role 
in their virulence. The capsule polysaccharide of C. freundii is essential to its ability to adhere to 
many tissues and implanted devices, resulting in various nosocomial infections that are often 
highly resistant to antibiotic therapies. Nosocomial K. pneumoniae infections are also due to 
bacterial populations within a fully established biofilm at the site of infection, further 
complicating treatments options (36). Therefore, investigation is needed to evaluate new 
methods of treating biofilm-based infections among species within the Enterobacteriaceae 
family.  
Bacteriocins: 
 Bacteria often exist in hostile environments that only provide a limited amount of a space 
and resources for growth. Therefore, bacteria have evolved a variety of methods to outcompete 
their bacterial neighbors for the vital resources present within the surrounding environment. One 
effective method to compete for resources is the production of bacteriocins. Bacteriocins are 
polypeptides produced by the bacterial ribosome that inhibit the growth of closely related 
bacterial cells within the surrounding environment (37). Nearly all bacterial species produce a 
variety of bacteriocins. These toxic proteins have different bactericidal mechanisms, such as 
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being a potent nuclease, or a lytic peptidoglycanase, or others (38). Due to their high bactericidal 
nature, bacteriocins are continuing to be investigated for their potential applications in clinical 
medicine. Bacteriocins may have fantastic clinical results against bacterial infections due to their 
highly specific host range, or the cells they can inhibit, which mimics the selective toxicity of 
many natural antibiotic compounds. The high bactericidal activity and surprising stability of 
these secreted enzymes may lend a new alternative mechanism to fight against bacterial 
infections that are growing in their resistance to normal antibiotic treatments.  
 The current literature supports that isolates of Klebsiella pneumoniae infections usually 
exhibit a high degree of bacteriocin production. More specifically, it was found that these 
Klebsiella bacteriocins were highly effective against E. coli and Shigella strains, both of which 
are of the Enterobacteriaceae family (39). It may be possible that specific bacteriocins of K. 
pneumoniae have the ability to recognize and kill Citrobacter cells. This postulation aligns with 
the existing understanding of bacteriocins and the infectious nature of Klebsiella and 
Citrobacter, both of which would be competing to form biofilms at a site susceptible to 
infection. Crude extracts of Enterobacteriaceae infection sites have been shown to result in the 
lysis of many related Gram-negative species, thus it may be possible to isolate a specific 
bacteriocin peptide that has a narrow-spectrum effectiveness against Citrobacter (40). It has also 
been observed in vivo that combining both existing antibiotic drug treatments along with 
bacteriocin treatment has the ability to produce a synergistic effect in inhibition of certain 
bacterial strains. For example, it has been shown that lower doses of a broad-spectrum antibiotic 
drug are needed to inhibit Staphylococcus aureus strains, when used in conjunction with a 
known bacteriocin of Staphylococcus species (41). Therefore, following this same model, 
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utilizing selectively toxic Klebsiella bacteriocins may be useful in limiting the antibiotic dosage 
necessary to inhibit Citrobacter due to a synergistic bactericidal mechanism.   
Streptomycin, a Broad-Spectrum Antibiotic: 
 Antibiotic drugs are broadly categorized as either being a broad or narrow-spectrum drug 
compound. This classification is based upon the specific bactericidal or bacteriostatic mechanism 
of the drug. Narrow-spectrum antibiotics are those which have a mechanism that specifically 
inhibits a certain structure within the bacterial cell (42). For instance, penicillin is a narrow-
spectrum antibiotic which is used against Gram-positive bacterial infections, as its mechanism 
inhibits cell wall synthesis, resulting in lysis of the cell (43). Narrow-spectrum antibiotics are 
used when the causative bacterial species is known. The use of a narrow-spectrum antibiotic 
agent is desirable over a broad-spectrum drug in that it will only inhibit the growth of specific 
bacteria, and limit the amount of harm done to existing bacterial populations within the human 
microbiome. Electing for the use of a narrow-spectrum drug can also help lessen the spread of 
antibiotic resistant pathogens by eliminating the propagation of persistent cells that would 
survive the effects of a broad-spectrum drug (44). Broad-spectrum antibiotics work by inhibiting 
a structure or process that is common to nearly all bacterial cells. Consequently, these drugs are 
also highly effective in killing billions of other resident bacterial cells within our body. Those 
they do not kill are then highly resistant to the given drug. Therefore, it is extremely important to 
steward the use of broad-spectrum antibiotics in order to slow the expansion of bacterial 
resistance.  
 Streptomycin is one example of a broad-spectrum antibiotic drug, and the drug to be 
particularly investigated within the study. Streptomycin is a broad-spectrum drug in the sense 
that it inhibits the function of the bacterial ribosome, therefore interrupting the cell’s ability to 
synthesize the proteins it needs for growth and metabolism. More specifically, Streptomycin 
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functions by binding to the 16s rRNA in the 30s subunit of the bacterial ribosome, thereby not 
allowing the initiator tRNA (N-formyl-methionine) from binding at the initiation step of 
translation (45). Resistance to Streptomycin has been observed by mutations within the gene for 
the S12 protein of the 16s rRNA, which make the rRNA strand of the ribosome no longer 
recognizable as the target compound by the Streptomycin molecule (46). Various species within 
the Enterobacteriaceae family have exhibited extensive resistance to Steptomycin. The typical 
prescribed treatment of Streptomycin costs more than $200 (47). In order to better steward the 
use of broad-spectrum antibiotics, here Streptomycin is used as a model drug to investigate 
whether dosage can be reduced by utilizing a potential KP bacteriocin in order to reduce the 
spread of resistant bacterial strains, preserve the patient’s existing microbiome, and save money.  
Present Work: 
 The main objectives of this research project are to determine the extent of CF inhibition 
yielded by the combined treatment of the KP molecule alongside streptomycin, and observe the 
synergistic effect of this combined treatment compared to streptomycin treatment alone. Another 
objective was to observe if it was possible to decrease the MIC of streptomycin when used in 
conjunction with the KP molecule, thereby limiting the selective pressure fueling spread of 
resistant bacteria. Since many of these resistant bacteria often exist within biofilms, it also tests 
the combined treatment’s potential use even after a bacterial biofilm has been established. 
Ultimately, the study serves as a model for the characterization of other potential poly-microbial 
interactions that could be used clinical settings to combat resistant infections.  
Materials and Methods 
Microbial Growth and Standardization: 
 Klebsiella pneumoniae ATCC® 13883TM was the main strain used throughout the study 
to investigate the bactericidal effects of supernatant protein(s) present. Klebsiella pneumoniae 
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ATCC® 9997TM was used a control strain. These were tested against Citrobacter freundii 
ATCC® 8090TM. KP and CF subcultures were both derived from refrigerated, pre-existing solid 
LB stocks. Both KP and CF were inoculated into liquid LB for growth. 
Obtaining KP Supernatant and Molecule: 
 The compound of interest, the bactericidal protein, from the KP 13883 strain resides 
within the supernatant of the freshly grown cells. Aliquots from the fresh KP culture, were 
centrifuged at 10,000 rpm for 10 minutes in order to pellet out the live cells and leave the 
supernatant present in suspension. The supernatant was poured into a filtered 0.22-micron filter 
syringe that functioned to remove any unwanted cellular debris left over from the centrifugation 
process. After filtration, only the desired supernatant remained and was stored. The KP 
supernatant could be refrigerated at 4°C and still retain its bactericidal properties.  
Initial Screening of Inhibition 
 From a fresh, overnight LB culture of CF, 106 cells were taken from each in order to 
standardize the concentration of the live cells present. These aliquots were measured for their 
optical density by using a spectrophotometer (OD600). Based upon the given measurement for 
turbidity, the volume of the culture that contains 1 million (106) CF cells was normalized to 
OD600= 0.01. This was repeated with each new trial to obtain 1 million cells.  
 For an initial screening of the inhibitory effects of the KP supernatant, a solid LB agar 
plate was inoculated with a lawn of CF. KP supernatant was tested for its inhibition by applying 
a 20μL spot to four various regions on the CF lawn and then incubated overnight at 37°C.  
Kirby-Bauer Disk Diffusion for Susceptibility: 
 A traditional Kirby-Bauer disk diffusion protocol for determining a strain’s susceptibility 
to a particular antibiotic compound was performed. The protocol involved growing a duplicate of 
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solid LB agar plates with a lawn of CF, and then the same for two plates with KP 13883 lawns. 
Antibiotics disks were aseptically placed onto the agar plates. There were four such antibiotic 
disks on each plate to avoid any interference from drug interactions. The antibiotics disks used 
were as followed: penicillin (P10), chloramphenicol (C30), bacitracin (B10), ampicillin (AM10), 
tetracycline (TE30), streptomycin (S10), erythromycin (E15), and kanamycin (K30). These four 
plates were allowed to grow overnight in the 37°C incubator. Pictures were taken and zones of 
inhibition of each disk, measured for their diameter.  
Initial Screening for Effective Streptomycin Dosage against CF: 
 In order to observe if there was any synergistic effect of inhibition between the 
Streptomycin antibiotic drug and the KP molecule, it was necessary to determine the minimum 
inhibitory concentration (MIC) of the Streptomycin drug. Knowledge of the MIC of 
streptomycin would lend a general idea of what dosages would be effective at inhibiting CF 
growth alone, and if these could be improved by addition of the KP molecule to the treatment 
group. An initial screening for an estimate of the inhibitory concentration of streptomycin was 
conducted by placing a 20 μL aliquot of a 24-hour culture of CF into five x5mL. Doses of 
streptomycin were added to each tube at a concentration of 10, 20, 40, 60, and 80 μM, 
respectively. After overnight incubation, tubes were observed for turbidity and photographs were 
taken. From the tubes, 100 μL. of each was plated onto a LB agar plate and allowed to grow 
overnight at 37°C. The next day photographs of the plates were taken.    
Determination of Efficacy via Plating Serial Dilutions and Colony Forming Units: 
 The increased efficacy due to the addition of the KP molecule to the streptomycin 
treatment was also examined by using plated serial dilutions of each of four groups: a control of 
only CF, CF with the addition of standard dosing of streptomycin, CF with both streptomycin 
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and the KP molecule, and also CF with the KP molecule alone. Each of the test groups were 
from a test tube containing 5 mL of fresh LB, and 1 million CF cells were added to each of the 
four groups. The second test group had 300 microliters of a 50 μg/mL streptomycin stock added, 
resulting in a 50 μM concentration. The third test group had the same concentration of 
streptomycin present, but also 2 mL of KP molecule added. The fourth test group had only the 2 
mL of KP molecule added, and no streptomycin was present. After 24-hour growth, these 
cultures were then qualitatively assessed for turbidity, and comparative photographs were taken. 
A series of serial dilutions were performed in order to determine and compare countable, isolated 
colonies between each of the four test groups. This was done by taking 100 microliters of the 
culture and diluting into 900 microliters of PBS buffer (10-1). 100 microliters of this dilution 
level was then plated onto a LB plate. This was then repeated nine times as 100 microliters of 
each dilution level was withdrawn and diluted into 900 microliters. 100 microliters of every 
other dilution level (10-3, 10-5, 10-7, 10-9) was plated onto a fresh LB plate. After 24-hour growth, 
these five serial dilution plates were then counted for isolated colony forming units present. Any 
plate with global growth present (200+ isolated colonies) was considered too many to count 
(TMTC). Comparative photographs were taken of each of the serially diluted plates. 
Determining Minimum Inhibitory Concentration of Streptomycin and KP molecule: 
 Determination of minimum inhibitory concentration (MIC) of the treatments allowed for 
later comparison of the efficaciousness of singular drug treatment, or drug treatment alongside 
the KP molecule/bacteriocin. The determination of the MIC was performed on a 96-well 
microtiter well plate with decreasing volumes of streptomycin added from left to right, and 
decreasing amounts of the KP molecule added from top to bottom. After addition of 1 million CF 
cells to each of the 96 wells the KP molecule was added in decreasing volumes from top to 
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bottom. These volumes were decreasing increments of 25μL ranging from 200μL in row A to 
50μL in row G, with row H serving as a control. Once the appropriate volume of the KP 
molecule was added to the rows of the plate, decreasing doses of streptomycin was added to 
these columns from left to right as to half the molarity of streptomycin in each column. All cells 
were volumized to 250 mL with LB. After 24-hour growth, the turbidity and number of live cells 
present in each well was measured using spectrophotometry. For determination of the turbidity 
of the well plate, OD readings were taken at a wavelength of 595 nm. Pictures were also taken. 
Since spectrophotometers simply measuring turbidity will be influenced by left over cellular 
debris from dead cells (such as those killed by the KP molecule, streptomycin, or both), it was 
necessary to determine a procedure to measure only the live cells present within the cell by the 
use of an MTT assay. Upon 24-hour growth of the plate, 20 μL of MTT was added to all wells 
present on the plate. After addition of MTT, the plate was placed into 37°C incubation for 30 
minutes to allow the reduction of the MTT to occur by viable cells present. After incubation, 
200μL of acidic isopropanol was added to all wells in order to dissolve the formed precipitate, 
thus forming the purple-colored solution from the formazan. After the addition of the acid, an 
OD reading was taken at 450 nm. Pictures were also taken after the MTT procedure. 
Comparing Inhibition of Planktonic and Biofilm Populations of Citrobacter: 
 A protocol was performed to investigate the ability of the KP molecule to inhibit CF 
growth at different stages of biofilm development. This 2-day protocol compared the growth of 
CF on a control plate having only streptomycin added, and the other plate having both 
streptomycin and the KP molecule added. 100μL of fresh LB was added to all the wells of the 
plate, other than row B. 1 million CF cells was added to all wells in the plate. After addition of 
both the CF and the streptomycin, the control plate was volumized the addition of 1250μL of 
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fresh LB in order to determine the inhibition of growth by streptomycin alone. The experimental 
plate was instead volumized using 1250μL of the KP molecule. These plates were then allowed 
to grow for 24 hours in 37°C incubation. KP molecule and streptomycin added upon initial 
inoculation tested the efficacy at attachment. In order to investigate the efficacy of inhibition of 
the streptomycin and KP molecule after the CF biofilm phase, it required that the LB and 1 
million CF cells were added to the well plate and then allowed to grow in incubation overnight. 
Once both the planktonic and the biofilm attachment phase plates had undergone 24-hour 
growth, pictures were taken to qualitatively assess turbidity. OD readings were taken using three 
methods per plate for both the planktonic and biofilm growth plates. For columns 1-4 of the 
plate, a simple OD reading at 595 nm was taken to assess the turbidity of the wells in these 
columns. For the columns 5-8 of the plate, another MTT procedure was performed by the 
addition of 10μL of 0.5mg/mL MTT and incubation in 37°C for 10 minutes. After incubation, 
200μL of DMSO was added in order to dissolve the precipitate. After the MTT protocol was 
performed, an OD reading was taken at 450 nm, which allowed for the measurement of the live 
CF cells present within the well. In order to visualize the biofilm development present in the 
wells, a staining procedure involving 0.001% aqueous crystal violet (CV) stain was used in 
columns 9-12. Before addition of CV stain, the liquid was removed from the wells so that only 
the attached biofilm was left within the well. PBS was used to rinse unattached cells, and then 
200μL of CV was then added and allowed to sit for 5 minutes. The CV stain was then removed, 
followed by a similar PBS rinse to remove unattached dye. This PBS was removed and the well 
was allowed to dry. Finally, glacial acetic acid was added to the well in order to solubilize the 
stain attached to cells within the biofilm. After this staining and washing, an OD reading was 
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taken at 595 nm. Pictures were taken both before and after the addition of the visualization 
reagents. 
Biofilm Growth and Inhibition Imaging: 
 In order to visualize the growth of the CF biofilm present on a surface, a staining protocol 
was followed to allow for subsequent imaging of the growth. In the same testing groups as 
previously used, CF cells were exposed to treatment groups at both the attachment phase and the 
biofilm phase of growth. A cover slip was used to provide a surface for biofilm development. A 
Gram stain procedure was used to stain the bacteria. After drying, pictures were taken at 1000x 





Results and Discussion 
Initial Screening of Inhibition: 
 
Figure 1: Screening KP cell, KP molecule from supernatant, and lyophilized KP on a CF lawn 
 
Figure 2: Screening of KP molecule on CK lawn showing no inhibition 
 Seen above are aliquots of the KP intact cell, the KP supernatant, and the KP lyophilized 
KP placed on a CF lawn (Figure 1). This figure shows screening for the efficacy of all three of 
the forms of the KP molecule. It was known that a secreted protein of the KP supernatant, 
referred to as the KP molecule, effectively inhibited the growth of certain species within the 
Enterobacteriaceae family. You can observe the increased ability to inhibit the CF when in the 
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supernatant or lyophilized forms. This supports the notion that this inhibitory compound is 
indeed a molecule housed within the KP cell, rather than the intact cell itself. However, certain 
species within the family were not sensitive to the KP molecule (Figure 2). The KP molecule 
lends no inhibition of Citrobacter koseri, a similar relative to Citrobacter freundii. Much of the 
antimicrobial range was established by Seth Jewett, a fellow ETSU Honors-in-Discipline lab 
mate, under the direction of Dr. Sean Fox. From his experimentation, Jewett observed that C. 
freundii and E. cloacae were highly sensitive to the KP molecule. C. freundii was confirmed to 
be highly sensitive to the KP molecule (Figure 1). Therefore, further investigation was pursued 
using C. freundii as the model organism for subsequent testing. As Jewett had also noted, C. 
koseri expressed no sensitivity to the KP molecule. Thus, investigating the action of KP 
molecule against C. freundii compared to its lack of inhibition against C. koseri may lead to 
further understanding the mechanism of the secreted protein.  
 
Figure 3: Comparisons of KP strain 13883 (bottom spots) and KP 9997 (top spots) 
 
 KP strain 13883 demonstrates the ability of the to inhibit the growth of both CF and 
Enterobacter cloaceae (EC) lawns (Figure 3). It shows that the ability to inhibit the growth of 
these species is specific to the 13883 strain, as the KP 9997 showed no inhibition of either 
species. Therefore, we knew that it was not a random mutagen within our laboratory that had 
caused this said inhibitory effect. Furthermore, it is interesting to observe how the 13883 strain is 
able to inhibit both CF and EC, yet not be able to inhibit C. koseri (CK). After genetic 
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investigation, it is known that CF and EC are genetically more similar to KP than CK is. This is 
further reason to believe that the KP molecule is likely to be a bacteriocin, as it inhibits those 
species that are most similar to itself. Therefore, it is logical to postulate that the KP molecule 
may be recognizing the genetically similar CF and EC cells by some shared recognition factor. 
However, the CK cells would not contain the said recognition factor, and thus would not be 
recognized as a competitor cell and there would be no inhibitory effect observed from the KP 
molecule/bacteriocin. 
 
Figure 4: KP cells (top left), KP molecule (top right), and KP molecule lyophilized (bottom) 
 
 Various forms of the Klebsiella show differences in their inhibition of CF (Figure 4). The 
top left shows simply the intact KP cells which give a modest zone of inhibition. The top right 
shows the increased extent of inhibition whenever the KP cell is taken out through a 
centrifugation and filtering procedure to simply receive the supernatant (see methods). The 
supernatant of the KP has a heightened ability to inhibit the CF lawn (Figure 4). As we had 
suspected the KP molecule to be a bacteriocin, we were curious as to whether taking the KP 
supernatant through a lyophilization procedure would increase the inhibition of CF since the 
liquid portion of the KP supernatant would be removed. The lyophilized KP yielded even greater 







The observation of increased inhibition while within the supernatant form, and even more when 
lyophilized (liquid of supernatant removed leaving only solid molecules present) lends further 
evidence to the hypothesis that the KP molecule is indeed a bacteriocin.  
Kirby-Bauer Disk Diffusion for Susceptibility: 
Citrobacter freundii 
Antibiotic Zone of Inhibition (mm) 
Penicillin (P10) 0 
Chloramphenicol (C30) 1.8 
Bacitracin (B10) 0 
Ampicillin (AM10) 0 
Tetracycline (TE30) 1.6 
Streptomycin (S10) 1.7 
Erythromycin (E15) 0 
Kanamycin (K30) 1.8 
Table 1: Kirby-Bauer Results showing zones of inhibition for CF 
Klebsiella pneumoniae 
Antibiotic Zone of Inhibition (mm) 
Penicillin (P10) 0 
Chloramphenicol (C30) 1.8 
Bacitracin (B10) 0 
Ampicillin (AM10) 0 
Tetracycline (TE30) 1.5 
Streptomycin (S10) 1.6 
Erythromycin (E15) 0 
Kanamycin (K30) 2 
Table 2: Kirby-Bauer Results showing zones of inhibition for KP 
 The intent behind performing a Kirby-Bauer test for antibiotic sensitivity/susceptibility 
was to establish which drug(s) would be beneficial to test for potential synergistic properties with 
the KP molecule. The drugs that would be potential candidates for further research are those 
which exhibit a slight zone of inhibition that indicates their susceptibility, but not large enough 
where the drug is already highly effective against the bacteria. Furthermore, it was important that 
CF was slightly susceptible to the drug so that a synergistic effect could be observed alongside of 
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the KP molecule. The antibiotic profile of KP was also obtained in order to ensure any results 
that were contrary to expectations were not due to a given antibiotic causing some sort of 
inhibition of the KP molecule itself. As observed from Table 1 and Table 2 (p.27), four such 
drug candidates resulted, chloramphenicol, tetracycline, streptomycin, and kanamycin. From the 
performed Kirby-Bauer test, each of these drugs exhibited a zone of inhibition that was greater 
than 0 mm yet still less than or equal to 2 mm. This measurement indicated their present, yet 
incomplete, inhibition of both CF and KP. Streptomycin was chosen as the drug to be tested for 
its potential synergy alongside the KP molecule into the inhibition of CF. The decision to test 
streptomycin as the drug of choice was due to knowledge of reported clinical cases of 
Enterobacteriaceae species, such as CF, having resistance to streptomycin (see more within 
introduction, pp. 14, 15).  
Screening for Effective Streptomycin Dosage against CF 
 
Figure 5: Determining Effective Streptomycin Dosage  
 
 In order to test whether addition of the KP molecule to a treatment protocol would allow 
for a decreased dosage of streptomycin, it was first necessary to determine the minimum 
inhibitory concentration (MIC) of streptomycin that is needed to inhibit the growth of a standard 
culture of C. freundii.  After a review of current literature regarding inhibition of 
Enterobacteriaceae, we began by testing various concentrations of streptomycin dosages ranging 
from 10 μM to 80 μM followed by plating (Figure 5). As seen by the plating, there was an 
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obvious decrease in the growth of CF present on the 60 μM dosage compared to the 40 μM 
dosage.  
 
Figure 6: Plating Showing Estimation of Streptomycin MIC 
 
 There was a significant increase in the inhibition of CF as the streptomycin dosage was 
increased from 40 to 60 μM (Figure 6). Therefore, the test was effective at providing an 
estimation of the MIC for the streptomycin at 50 μM. This is an estimation of the minimum 
concentration of streptomycin in a dose that could provide effective inhibition against a standard 
culture of CF. This value could then be used a reference to see if the addition of the KP molecule 
to the treatment could decrease the concentration of Streptomycin needed within an effective 
dose and also lend an increased inhibitory effect through a synergistic mechanism.   
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Determination of Efficacy via Plating Serial Dilutions of Treatment Groups: 
 
Figure 7: Comparing inhibition of KP + Streptomycin with KP alone and Streptomycin alone 
 
 The treatment of KP and streptomycin together is synergistic in some way, and yields a 
greater extent of inhibit of the CF present (Figure 7). The trials performed in Figure 7, such as 
the one seen above, had LB plates diluted out seven times in order to find countable colonies of 
CF. As you can see, the control with CF alone yielded colonies that were too high to count out to 
the fifth dilution at 1:10000, and created a solid lawn at the first dilution. The treatment of 
streptomycin alone and the KP molecule alone both also acted in a similar manner, still resulting 
in a dense lawn of growth at the first dilution level. However, when the treatment of KP 
molecule and streptomycin is combined, there is a drastic decrease in the growth of CF even at 
the first dilution level. Compared to the lawn of CF growth under the treatments of KP molecule 
and CF alone, the KP + Streptomycin yielded a heightened ability to inhibit the growth of CF. 
This was observed by having less than 100 countable CF colonies on the first dilution level 
(Figure 7). Therefore, such plating trials qualitatively demonstrate the ability of the KP molecule 
CF only 
KP molecule only 
Abx only 




and Streptomycin to have a synergistic ability to inhibit the growth of CF. The term “synergistic” 
inhibition is used as the combined treatment yields a greater extent of inhibition in comparison to 
each individual treatment by itself. Although these trials do not explain the mechanism of the 
inhibition, it clearly indicates its efficacy in vitro.  
Spectrophotometric Analysis of Effective MIC of Streptomycin and KP molecule 
 
Graph 1: Spectrophotometric reading following MTT procedure to find MIC 
 
 The minimum inhibitory concentration (MIC) is a general measurement of how much of 
a particular antimicrobial agent is needed to inhibit the visible growth of a given organism after 
an overnight incubation. Therefore, a MIC value that is lower indicates that a particular 
antimicrobial agent is effective at inhibiting the growth of that particular test organism. These 
values help clinicians better assign an appropriate dosage of antibiotics while treating a patient 
with a given infection. Failure to assign a dosage that at least meets the MIC for the particular 
drug and bacteria can expose the bacterial population to selective pressure that results in the 


























MIC’s have not been established for given antibiotic/bacteria interactions. After observing that 
the combined treatment of KP molecule + Streptomycin was more effective than each of these 
treatments individually, it was necessary to determine the MIC of them combined.  
 Graph 1 shows a distinct decrease in the growth of CF in the fourth column labeled “C3”. 
The absorbance from spectrophotometric analysis gave an absorbance value of approximately 
0.5 on average, which is nearly less than half of the absorbance values given with KP only and 
Streptomycin only treatments (approx. 1.0). Recall that these trials tested the growth of CF at 
various combinations of KP molecule + Streptomycin combined treatment. Therefore, the 
absorbance value at the C3 indicates that there is some middle ground in the effectiveness of the 
combined treatment where it is more effective than there being a greater majority of nearly all 
KP molecule or nearly all Streptomycin in the treatment. C3 had a combined treatment of 150 μL 
of KP molecule and a streptomycin concentration of 32 μM. Columns A1 and B2 have a greater 
amount of KP molecule added than C3 but less streptomycin added, while columns D4-H8 have 
less KP molecule than C3 but more streptomycin added. Note that the combined treatment 
allows the MIC of streptomycin needed to inhibit the growth of CF drops from approximately 50 
μM from initial screenings of streptomycin, down to at least 32 μM or less when combined with 
the KP molecule in an appropriate dosage. This indicates that CF is most effectively inhibited 
while the treatment cocktail is composed of moderate amounts of both KP molecule and 
streptomycin rather than a dosage of only one or the other. Furthermore, it is advantageous to 
limit the dosage of antibiotic drugs, such as streptomycin, needed to inhibit a bacterial infection. 
As seen from these trials, compounds such as the KP molecule can be effective in allowing a 
decrease in the MIC of certain antibiotics, thereby limiting the development of persistent multi-
drug resistant bacterial populations. 
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 This colorimetric MTT assay procedure was performed after initial readings of turbidity, 
as it is an irreversible end-point reaction that reflects the number of viable cells present. MTT 
(IUPAC name 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) is a yellow-colored 
tetrazole that is reduced to a purple-colored compound called formazan within viable cells. This 
reduction is carried out by oxidoreductases present in viable cells. Upon formation of the 
insoluble purple formazan, an acidic reagent is added to the well to dissolve the precipitate, 
allowing for photometric reading the purple-colored solution present. 
Comparing Inhibition of Planktonic and Biofilm Populations of Citrobacter: 
 
Graph 2: Measuring CF growth after KP + Streptomycin treatment at Attachment Phase 
 
 Graph 2 gives a graphical representation of the absorbance readings at various treatment 
levels with increasing amounts of Streptomycin concentration when treated at attachment phase 
of CF growth. The turbidity readings served to show the overall cell density of the CF growth, 
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molecule and streptomycin decreases the turbidity readings by more than half at the MIC value 
of 32 μM. The trend of decreases in turbidity at each treatment level follows this pattern even as 
the concentration of streptomycin used is decreased, although the magnitude of difference in 
turbidity between combined treatment and streptomycin treatment alone does decrease as the 
streptomycin concentration decreases. The MTT readings serve as an indicator of the amount of 
viable cells left remaining in the culture, as the MTT reagent is a substrate that only 
metabolically active cells react with, resulting in a distinct color that is measureable on the 
spectrophotometer. At the MIC of streptomycin (when in combined treatment with KP molecule) 
at 32 μM, the MTT reading is only approximately a third of the control reading. This indicates 
that not only does the combined treatment of KP molecule and streptomycin decrease the overall 
turbidity of the CF culture, it also decreases the proportion of these cells that are viable within 
the culture. This means that a significant amount of the cell density, measured as turbidity, is 
resulting from dead CF cells. The crystal violet (CV) staining procedure allowed a measurement 
of the estimated cellular mass accrued as the CF culture grew. It is known that CF infections 
often exist in a biofilm state, which increases the overall cell mass as exopolysaccharides are 
produced by cells within the developing biofilm. The CV stain was taken up by the cells and 
their cell wall and then rinsed, and then expelled through the lysing steps, which enables the 
extent of the CV stain released to be an indicator of the overall cell mass present within the 
culture. There were significantly decreased absorbance readings after CV staining under the 
combined treatment in comparison to the individual streptomycin treatment (Graph 2). This 
indicates the combined treatment is effective as inhibiting CF’s ability to initially form a biofilm. 
The inhibition of biofilm formation is important clinically, as it allows the bacterial infection to 
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remain more susceptible to other antibiotic treatment options and be less adherent to other 
internal body surfaces or implants.  
 
 
Graph 3: Measuring CF growth after KP + Streptomycin treatment at 24 hours 
 
 Graph 3 shows the same measurements as Graph 2, except the CF culture was exposed to 
the combined treatment of the KP molecule and the Streptomycin after 24 hours of growth. This 
24 hours of undisturbed CF growth allows the bacterial populations to aggregate and form dense 
biofilms (see Figure 8a), which lends increased resistance to antibiotics and ability to resist 
human immune defenses. In a similar manner to the combined treatment in the attachment phase, 
the combined treatment after 24-hour CF growth yielded a significant decrease in turbidity when 
the MIC of streptomycin was administered (32 μM). When compared to the control, the 32 μM 
streptomycin and KP molecule treatment yielded a decrease in absorbance from approximately 
1.3 to 0.2. Likewise, the combined treatment helped to decrease the density of the established CF 
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treatment, the MTT readings of the CF growth indicated that a lesser amount of the cell density 
present was derived from viable cells. The CV staining procedure also yielded absorbance 
readings that indicate the biofilm that had been established during the initial 24 hours of growth 
was reduced in mass. However, the CV staining procedure is rather technique sensitive, as 
removing the staining and rinsing agents without touching the biofilm of the CF can be quite 
difficult. Further experiments investigating the effects of the combined treatment on established 
CF biofilms is needed to fully understand its extent and mechanism of inhibition. Despite 
technique limitations, the combined treatment of the KP molecule alongside an appropriate 
dosage of streptomycin does seem to effectively inhibit CF growth, even after the bacterial 
population has been able to establish a biofilm. The observed efficacy of the combined treatment 
makes the KP molecule an obvious avenue for further research into its interaction with other 




Biofilm Growth and Inhibition Imaging: 
 
Figure 8: Microscopy revealing treatment outcomes after 24-hours CF biofilm growth; 8a) 
Control CF only; 8b) Streptomycin only; 8c) KP molecule only; 8d) KP molecule+Streptomycin 
 
 Light microscopy imaging was used to help visualize the increase in inhibition when 
there is CF exposed to a combined treatment of both KP molecule and a dosage of streptomycin 
(Figure 8). The CF lawns grown were allowed to grow undisturbed for 24 hours to allow the 
formation of a dense biofilm. The biofilm of uninhibited CF is seen well in 8a, where there are 
dense populations of aggregated bacterial growth. It is known these dense biofilms are of clinical 
importance, as they make the bacterial populations more resistant to antibiotics and other means 
of traditional treatments. Figure 8b (Streptomycin only) shows the moderate inhibition of the CF 
biofilm, while 8c (KP molecule) shows an even more pronounced inhibition than does the use of 





bacterial population is exposed to a combined treatment of both KP molecule and Streptomycin. 
Figure 8 serves as a visualization aid to the data presented in Graph 3, which highlights the 
increased inhibition of CF biofilms when exposed to both the KP molecule and Streptomycin, as 
opposed to just one individual treatment. The combined treatment’s ability to inhibit CF growth 
even after the infection has had adequate time to develop a dense biofilm further solidifies its 
potential as a valuable clinical treatment modality. 
 
Figure 9: Microscopy revealing treatment outcomes at CF attachment phase; 9a) Control CF 
only; 9b) Streptomycin only; 9c) KP molecule only; 9d) KP molecule + Streptomycin 
 
 Light microscopy imaging was used again to help visualize the inhibitory effect of the 
combined treatment of the KP molecule and Streptomycin against CF at attachment phase 
(Figure 9). Figure 9a shows CF growth that has yet to develop dense biofilm populations. 9b 





and the KP molecule to individually inhibit CF. 9d shows the nearly complete inhibition of the 
CF growth when the CF is exposed to the combined treatment of the KP molecule and 
Streptomycin together when used at the attachment phase of CF growth. Imaging supports the 
combined treatment’s potential efficacy in clinical scenarios at multiple stages of CF infection, 
both before and after initial CF biofilm formation, as examined within this experiment.  
Conclusions 
 Citrobacter freundii is simply one species among hundreds of pathogenic bacteria that 
continue to evolve greater resistance to several previously reliable antibiotic medications. Novel 
antibacterial compounds and treatment modalities must urgently be researched and developed to 
combat the effects of such resistant strains. Within this research presented, one means of 
combating resistant bacteria may be to incorporate antimicrobial compounds derived from 
competitor species. The research presented exhibits the use of a suspected bacteriocin from 
Klebsiella pneumoniae as one such inhibitory compound. Future needed research endeavors 
include investigation into the mechanism of the KP molecule and its efficacy within an animal 
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